Immunocore announces first patient dosed in Phase 1 trial of IMC-P115C

Immunocore (IMCR) Holdings announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C which is a half-life extended ImmTAC candidate. IMC-P115C was developed to improve patient convenience by reducing the frequency of treatment administration. It is Immunocore’s first half-life extended candidate, and sixth ImmTAC candidate to enter the clinic. IMC-P115C is a PRAME x CD3 ImmTAC bispecific protein, with the same CD3 and targeting the same HLA-A*02:01 PRAME, or PReferentially expressed Antigen in MElanoma, peptide as brenetafusp. The Phase 1 dose escalation trial will evaluate the safety, pharmacokinetics and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with a range of advanced cancers expressing PRAME.